The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i).

Komal  Jhaveri

Consulting or Advisory Role - Abbvie; Arivinas; AstraZeneca; BeOne Therapeutics; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bridge Bio Oncology and Rayzebio; Bristol-Myers Squibb; ConcertAI; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Halda Therapeutics; Lilly; Mersana; natera; Novartis; Olema Pharmaceuticals; Pfizer; Precede Bio; RAYZEBIO; Relay Therapeutics; Sanofi; Scorpion Therapeutics; Seagen; Zymeworks

Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Bridge Bio Oncology Therapeutics; Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck; Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical

Hope  Rugo

Consulting or Advisory Role - BioNTech; Bristol Meyer; Helsinn Therapeutics; Napo Pharmaceuticals

Research Funding - Ambryx (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Daiichi Sankyo (Inst); F. Hoffman-La Roche/Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)

Sara  Tolaney

Consulting or Advisory Role - AADi; Aktis Oncology; Ambrx; Arvinas; AstraZeneca; Avenzo Therapeutics; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Boehringer Ingelheim; Boundless Bio; Bristol-Myers Squibb; Celcuity; Circle Pharma; Corcept Therapeutics; Cullinan Oncology; Daiichi Sankyo; Denali Therapeutics; eFFECTOR Therapeutics; Eisai; Ellipses Pharma; Genentech; Immunomedics/Gilead; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Novartis; Olema Pharmaceuticals; Pfizer; Reveal Genomics; Samsung Bioepis; Seagen; Summit Therapeutics; Systimmune; Tempus; Zuellig Pharma

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - Arvinas; AstraZeneca; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Roche

(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences

Miguel  Martin

Stock and Other Ownership Interests  - AstraZeneca; Pfizer

Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN

Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; ROVI Spain; STEMLINE-MENARINI

Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech

Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Daichii-Sankyo

Other Relationship - AstraZeneca; Novartis; Roche

Gregory  Vidal

Employment - Novartis (I)

Stock and Other Ownership Interests  - Novartis (I)

Consulting or Advisory Role - Arvinas; AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Merck; Myriad Genetics; Novartis; Pfizer; Seagen; Stemline Therapeutics; Tersera

Speakers' Bureau - AstraZeneca

Research Funding - AstraZeneca/MedImmune; BioNTech SE (Inst); Bristol-Myers Squibb; Celcuity; Daiichi Sankyo; EMD Serono; Genentech/Roche; Gilead Sciences; GlaxoSmithKline (Inst); Lilly; Myriad Genetics; Natera; Puma Biotechnology; Tesaro

Travel, Accommodations, Expenses - AstraZeneca

Luca  Moscetti

Honoraria - Gilead Sciences; Lilly; Roche/Genentech

Consulting or Advisory Role - AstraZeneca; Roche; Seagen; Seagen

Travel, Accommodations, Expenses - Lilly; Pfizer; Pfizer

Adam  Brufsky

Consulting or Advisory Role - Agendia; Ataraxis; Celcuity; Daiichi Sankyo/Lilly; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology

Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)

Expert Testimony - Pfizer; Sanofi

William  Gradishar

Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Gilead Sciences; merck; Novartis; Pfizer

Andreas  Schneeweiss

Honoraria - Amgen; AstraZeneca; Aurikamed; ClinSol; coma UroGyn; Connectmedica; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; I-MED; if-kongress; iOMEDICO; Lilly; MCI Deutschland; MSD; Novartis; Onkowissen; Pfizer; Promedicis; Roche; Seagen; Streamedup!

Research Funding - Roche Pharma AG (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Pfizer; Roche

Naoki  Niikura

Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; MSD; Novartis; Pfizer

Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Mochida Pharmaceutical Co. Ltd. (Inst); Novartis (Inst); Pfizer

Anne  Favret

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Margarita  Alfie

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Keun Seok  Lee

Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche

Research Funding - Dong-A ST (Inst); Novartis (Inst)

Sarah  Khan

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Kristin  Griffiths

Employment - Genetech, Inc.

Stock and Other Ownership Interests  - Roche

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Lisa  Lam

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Merilin  Feldman

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Bann-mo  Day

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Pablo  Pérez-Moreno

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Other Relationship - Support for third-party writing assistance for this abstract, furnished by Bena Lim, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Erica  Mayer

Consulting or Advisory Role - AstraZeneca; Atkis; Genentech; Lilly; Novartis